Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer
Bone Metabolic Markers, TRAP, and Zometa's Effect on Bone Metastasis Due to Lung Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- James Graham Brown Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- invasive lung cancer (small cell or non-small cell lung cancer)
- osteolytic bone metastasis determined by clinical exam, bone scan/XR
- age > 18 years
Exclusion Criteria:
- concurrent malignancy with a second primary
- renal failure (serum creatinine > 3mg/dl)
- pregnancy
- active rheumatoid arthritis
- intolerance to zoledronic acid
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: zoledronic acid
3.0-4.0
mg by IV (in the vein), once a month for 6 months
|
3.0-4.0
mg by IV (in the vein), once a month for 6 months
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Average Percent Change From Baseline in TRAP Levels at 2 Weeks
Time Frame: TRAP levels at Baseline and 2 weeks after first Zometa infusion
|
Change was calculated as 100% (value at baseline minus value at 2 weeks)/value at baseline
|
TRAP levels at Baseline and 2 weeks after first Zometa infusion
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Goetz H Kloecker, MD, MSPH, James Graham Brown Cancer Center/ University of Louisville
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Neoplastic Processes
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma
- Neoplasm Metastasis
- Small Cell Lung Carcinoma
- Carcinoma, Small Cell
- Physiological Effects of Drugs
- Bone Density Conservation Agents
- Zoledronic Acid
Other Study ID Numbers
Other Study ID Numbers
- 565.04
- BCC-LUN-04-002 (Other Identifier: James Graham Brown Cancer Center Clinical Trials Office)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.